Extended Data Fig. 8: Immune infiltrates analysis in KL tumors after ULK1 inhibitor treatment.
a, Gating strategy used for immune analysis. b, FACS analysis of CD4 + (left) and CD8 + (right) T lymphocytes among total tumor infiltrating CD45 + leukocytes in KL tumor after the treatment of ULK1 inhibitor MRT68921 (MRT). Veh n = 12, MRT n = 5 tumors each group. (mean ± sd, unpaired t test, two tailed). c, CD8/Treg ratio of total tumor infiltrating leukocytes (TILs) after the indicated drugs treatment. veh n = 12, MRT n = 5, MRT + PD1 n = 12 tumors each group. (mean ± sd, unpaired t test, two tailed). d, CD69, CCR7 and 2B4 levels within CD8 + T cells after MRT68921 (MRT) and anti-PD1 treatment. Left panel, veh n = 12, MRT + PD1 n = 10. Middle and right panel, veh n = 8, MRT + PD1 n = 10 tumors each group. (mean ± sd, unpaired t test, two tailed.).
